WO2023002399 - DOSING REGIMEN FOR AN NLRP3 INHIBITOR IN THE TREATMENT OF OSTEOARTHRITIS
National phase entry:
Publication Number
WO/2023/002399
Publication Date
26.01.2023
International Application No.
PCT/IB2022/056695
International Filing Date
20.07.2022
Title **
[English]
DOSING REGIMEN FOR AN NLRP3 INHIBITOR IN THE TREATMENT OF OSTEOARTHRITIS
[French]
SCHÉMA POSOLOGIQUE POUR UN INHIBITEUR DE NLRP3 DANS LE TRAITEMENT DE L'ARTHROSE
Applicants **
NOVARTIS AG
Lichtstrasse 35
4056 Basel, CH
Inventors
COLEMAN, Laura
c/o Novartis Institutes for Biomedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139, US
FARADY, Christopher
c/o Novartis Pharma AG
Postfach
4002 Basel, CH
GATLIK, Ewa
c/o Novartis Pharma AG
Postfach
4002 Basel, CH
SCHIEKER, Matthias
c/o Novartis Pharma AG
Postfach
4002 Basel, CH
Priority Data
63/224,890
23.07.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1409 | |
| EPO | Filing, Examination | 6655 | |
| Japan | Filing | 592 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 12910 |
Total: 22140 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure relates to the field of pharmacy, particularly to an NLRP3 inhibitor for use in the treatment of osteoarthritis. The disclosure also relates to an NLRP3 inhibitor or a pharmaceutical combination comprising an NLRP3 inhibitor, and at least one further therapeutic agent, for use in the treatment of osteoarthritis; to a method for the treatment of osteoarthritis that involves administering an NLRP3 inhibitor or the combination; and to the use of an NLRP3 inhibitor or the combination for the manufacture of a medicament for the treatment of osteoarthritis.[French]
La présente invention concerne le domaine de la pharmacie, en particulier un inhibiteur de NLRP3 destiné à être utilisé dans le traitement de l'arthrose. L'invention concerne également un inhibiteur de NLRP3 ou une combinaison pharmaceutique comprenant un inhibiteur de NLRP3, et au moins un autre agent thérapeutique, destiné à être utilisé dans le traitement de l'arthrose; un procédé pour le traitement de l'arthrose qui implique l'administration d'un inhibiteur de NLRP3 ou de la combinaison; et l'utilisation d'un inhibiteur de NLRP3 ou de la combinaison pour la fabrication d'un médicament pour le traitement de l'arthrose.